Drug Profile
Afimetoran - Bristol-Myers Squibb
Alternative Names: BMS-986256; TLR 7/8 Antagonist - Bristol-Myers Squibb; TLR 7/8 inhibitor - Bristol-Myers Squibb; Toll-like receptor 7/8 antagonist - Bristol-Myers SquibbLatest Information Update: 19 Dec 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class 2 ring heterocyclic compounds; Acetamides; Antineoplastics; Indoles; Monoclonal antibodies; Piperidines; Pyridines; Skin disorder therapies; Small molecules; Triazoles
- Mechanism of Action Toll-like receptor 7 antagonists; Toll-like receptor 8 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Systemic lupus erythematosus
- Phase I Autoimmune disorders; Unspecified
- Discontinued Cutaneous lupus erythematosus
Most Recent Events
- 19 Dec 2023 Discontinued - Phase-I for Cutaneous lupus erythematosus in Germany (PO) (Bristol-Myers Squibb Pipeline, December 2023)
- 10 Nov 2023 Efficacy and adverse events data from a phase Ib trial in cutaneous lupus erythematosus presented at the ACR Convergence 2023 (ACR/ARP-2023)
- 10 Nov 2023 Pharmacodynamics data from preclinical trial in Cutaneous lupus erythematosus presented at the ACR Convergence 2023